Skip to main content
TipRanks
Go Ultimate75% OFF

Rockwell Med (RMTI) Risk Analysis

1,236 Followers
Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Risk factors show the challenges a company faces. Investors can consider the worst-case scenarios before making an investment. TipRanks’ Risk Analysis categorizes risks based on proprietary classification algorithms and machine learning. Rockwell Med disclosed 53 risk factors in its most recent earnings report. Rockwell Med reported the most risks in the “Finance & Corporate” category.

Risk Overview Q3, 2026

Source: the company's latest filing for the period ended Sep 30, 2026, filed Nov 12, 2026

Risk Distribution
53Risks
Sector Avg.Finance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Risk Change Over Time

Rockwell Med disclosed risks per quarterNo. of Risks303540455055Q3Q4Q12023Q2Q3Q4Q12024Q2Q3Q4Q12025Q2Q3Q4Q12026Q2Q3Showing: Q3, 2026
Risks removedRisks addedRisks changedRockwell Med Risk Factors
  • Share Price & Shareholder Rights - Risk 1
    The issuance of shares upon conversion of the convertible note could result in substantial dilution to our stockholders, and the convertible note will remain outstanding if required stockholder approval is not obtained.

    As part of the consideration for the Vantive Transaction, we will issue to an affiliate of Vantive a $25 million convertible note that will be convertible at the holder's option at any time into shares of our common stock at an initial conversion price of $14.94 per share, subject to adjustment, and that will bear interest at 3.0% per annum payable in kind by addition to principal. The conversion price increases on the same basis as ordinary PIK interest, so that such interest does not itself increase the shares issuable in respect of the original principal. Until our stockholders approve the issuance under Nasdaq rules, issuances upon conversion, together with other issuances required to be aggregated, may not exceed 19.99% of either the shares of common stock or voting power outstanding immediately before execution of the Purchase Agreement, to the extent the cap is required by Nasdaq rules. The note requires us to seek approval at stockholder meetings subject to specified timing and eligibility provisions, to resubmit the proposal at subsequent annual meetings if approval is not obtained and, in specified circumstances, to hold a special meeting at the holder's request. Stockholder approval is not a condition to completion of the Vantive Transaction. If approval is not obtained and the exchange cap prevents conversion, the applicable principal and accrued and unpaid interest will remain outstanding and continue to accrue interest in accordance with the convertible note. Conversion of the note would materially dilute existing stockholders and could result in an affiliate of Vantive becoming a significant stockholder. We have also agreed to use commercially reasonable efforts to register the shares issuable upon conversion for resale within the timeframe specified in the note, and the existence of the convertible note and the potential issuance or resale of those shares could adversely affect the market price of our common stock.

  • Accounting & Financial Operations - Risk 2
    The historical financial information for the acquired business may not be indicative of its performance as a standalone business, and we may not realize the anticipated strategic and financial benefits of the Vantive Transaction.

    The acquired business historically has operated as part of Vantive's broader organization and has not operated or historically been reported as a separate standalone business. Accordingly, its historical financial information may not reflect all costs associated with operating independently, and actual operating costs, working capital requirements, capital requirements and financial results following closing may differ materially from historical amounts and from the assumptions used by us in evaluating the transaction. The base purchase price generally will not be reduced for deterioration in the acquired business's operating performance after 2025. Separate closing adjustments apply, and a specified revenue-based adjustment applies if audited 2025 net revenue falls short of the unaudited amount provided to us by 20% or more, and the closing condition relating to the absence of a material adverse effect on the acquired business is subject to significant exceptions. Our expectations regarding the transaction are based on assumptions regarding, among other things, future revenues, profitability, customer retention, market opportunities, integration costs, foreign currency exchange rates and working capital requirements. Prior to the transaction, commercial activities in certain markets were reduced or discontinued, including through decisions not to pursue certain tenders or renewals, and certain supplier relationships were affected by reduced forecasts, loss of exclusivity, disputes or renegotiations. The Purchase Agreement permits Vantive to continue certain of these portfolio optimization initiatives before the closing. We may not be able to restore affected relationships, successfully compete for future tenders or achieve historical or projected levels of revenue and profitability. If the acquired business performs differently from our expectations, we may fail to realize some or all of the anticipated benefits of the transaction.

  • Accounting & Financial Operations - Risk 3
    The Vantive Transaction will significantly increase the complexity of our financial reporting, and we will depend on Vantive for the financial statements of the acquired business.

    The acquired business has never been reported as a standalone company, and its historical financial statements are carve-out statements prepared by Vantive with allocations of shared costs. We will rely on Vantive and its auditors to deliver the audited and interim financial statements of the acquired business that we need to satisfy the closing conditions and our SEC reporting obligations, including the requirement to file historical and pro forma financial information after the closing, and delays or deficiencies in those statements could delay the closing or limit our access to the capital markets. After the closing, we will need to bring the acquired business within our internal control over financial reporting, implement controls over operations in multiple countries and currencies, and account for the Vantive Transaction, including any goodwill and intangible assets recognized, which may later be impaired. Material weaknesses, restatements or late filings could result, and a failure to deliver required financial reports to the lender could be an event of default under the term loans.

  • Debt & Financing - Risk 4
    We may not complete the Vantive Transaction on the anticipated terms or timetable, or at all, and we do not have a financing condition to our obligation to complete the transaction.

    Completion of the Vantive Transaction is subject to a number of conditions, including required regulatory approvals, specified pre-closing restructuring and separation activities, completion of the separation of Vantive's information technology systems from those of Baxter International Inc. ("Baxter"), its former parent, delivery of audited financial statements of the acquired business for 2025 and 2026, execution of definitive transition services and manufacturing and supply agreements, and other closing conditions. Certain of these matters depend on Vantive or third parties and could delay or prevent completion of the transaction. Taking into account these conditions and the anticipated separation timetable, we currently expect the closing to occur in mid-2027. Either party may terminate the Purchase Agreement if the closing has not occurred by November 1, 2027,subject to two 90-day extensions if only regulatory approvals and specified other conditions remain outstanding, and further extension in certain enforcement proceedings. The closing therefore could be delayed into April 2028 or later, and expiration of the outside date does not automatically terminate the Purchase Agreement. We do not have a financing condition to our obligation to close the Vantive Transaction, and the Purchase Agreement provides for specific performance in appropriate circumstances. Accordingly, if the applicable closing conditions are satisfied, we may be required to close the transaction notwithstanding developments that do not give rise to a contractual right not to close. In addition, under the Securities Purchase Agreement relating to our Series X Convertible Preferred Stock, we need the consent of DaVita Inc. ("DaVita"), a customer and the holder of that preferred stock, to incur the seller financing described below. Obtaining that consent is not a condition to our obligation to complete the Vantive Transaction. If DaVita does not consent, we would need to fund the purchase price from other sources, which may not be available on acceptable terms or at all, or complete the Vantive Transaction in breach of the Securities Purchase Agreement, which could expose us to claims by DaVita and adversely affect our commercial relationship with DaVita. Until closing, management will continue to devote substantial time and resources to the transaction. If the transaction is delayed or not completed, we may incur significant advisory, financing, legal, integration-planning and other costs, as well as management distraction, without realizing the anticipated benefits of the transaction.

  • Debt & Financing - Risk 5
    The Vantive Transaction will substantially increase our indebtedness and liquidity requirements and could materially reduce our financial flexibility.

    We expect to fund the $125 million base purchase price with seller financing provided by affiliates of Vantive, consisting of $100 million of secured term loans, subject to adjustment, and a $25 million convertible note, except to the extent we elect to replace term loans with qualifying third-party financing. The term loans will be secured by a lien on substantially all of our assets and those of our domestic subsidiaries, including the assets of our existing concentrates business, and by a pledge of the equity of our subsidiaries, will bear interest at Term SOFR plus initial margins of 5.50% and 7.00% for the two tranches, respectively, increasing by 0.75 percentage points annually, and will mature six years after closing with no regular scheduled principal amortization, but subject to mandatory prepayments, including potential tax-related catch-up payments after the fifth anniversary. Interest is payable monthly; subject to specified conditions, interest on the first tranche may be paid in kind at an additional 0.50% annual rate, increasing the principal that must ultimately be repaid. We currently expect to service this debt primarily from the cash flow of the acquired business, which we do not yet control and which has not operated as a standalone company, and our existing operations alone may not generate sufficient cash flow to service it. We may replace all or a portion of the term loans with qualifying third-party financing, and the seller term loans will not be reduced for any shortfall in replacement-financing proceeds actually paid to Vantive. We remain obligated to deliver the full closing consideration if the applicable closing conditions are satisfied and Vantive provides the required seller financing. Vantive will retain the cash of the acquired business through the closing, and any cash left in the acquired entities at the closing will increase the purchase price and the principal of the term loans; in jurisdictions where the acquired business is transferred by asset sale, Vantive will also retain receivables that arose before the closing. As a result, we will need to fund the working capital of the acquired business from the closing. Our liquidity requirements in connection with the transaction may be significant and may include integration and stand-up costs, payroll, working capital, supplier payments, transition costs, professional fees and other expenses associated with operating the acquired business independently from Vantive. We may also be required to replace certain letters of credit, surety bonds, guarantees and other credit support or, in certain circumstances, provide cash collateral or other credit support, which could further reduce our available liquidity and borrowing capacity. Our increased indebtedness will require us to devote cash to interest and other debt-service obligations and could limit funds available for our businesses, capital expenditures or other strategic opportunities. The financing arrangements also contain restrictions on our operations and financing activities, including requirements to apply certain proceeds from equity issuances to repay indebtedness, and contain events of default, including cross-defaults, judgment defaults and the delisting of our common stock from Nasdaq, upon which the lender could accelerate the term loans and foreclose on the collateral, including the assets of our existing business. If our actual liquidity requirements exceed our expectations, we may need additional financing, which may not be available or may be available only on unfavorable terms. Vantive and its affiliates will simultaneously be our seller, our secured lender, the holder of the convertible note and a potential significant stockholder, a principal supplier of the acquired business and our transition services provider, and their interests in those capacities may differ from ours, including in any dispute under the Purchase Agreement.

  • Debt & Financing - Risk 6
    Our ability to raise capital through registered offerings, including under our at-the-market facility, may be limited by the need to file required financial statements of the acquired business and related pro forma financial information.

    The Vantive Transaction may require historical financial statements of the acquired business and related pro forma financial information in connection with registered offerings. The requirements depend on the acquisition's significance, the type and timing of the offering and, for use of an existing shelf registration statement before closing, whether the probable acquisition represents a fundamental change. Until the required information is available and filed, our ability to raise capital through the ATM facility or other registered offerings may be limited. Vantive is required to prepare and deliver specified audited and interim financial statements as promptly as practicable, but there can be no assurance they will be available when we need to raise capital. These limitations may continue after closing. Private placements could also be more costly or difficult to arrange if purchasers cannot promptly resell their securities under an effective registration statement. In addition, our ability to incur debt is limited by the consent right of DaVita described above, and while the seller term loans remain outstanding, net proceeds of equity issuances subject to the mandatory-prepayment provisions generally must first be applied in full to the second tranche and, after that tranche is repaid, 65% of the remaining proceeds must be applied to the first tranche, subject to specified exceptions. This limits the proceeds available to fund our operations. If we need additional capital during this period, we may be unable to obtain it or may obtain it only on unfavorable terms, which could require us to curtail investment in the acquired business or in our existing operations.

  • Debt & Financing - Risk 7
    The contingent consideration payable in connection with the Vantive Transaction could materially increase the ultimate cost of the transaction and affect our liquidity and flexibility in pursuing future strategic transactions.

    In addition to the $125 million base purchase price, the Purchase Agreement provides for up to $45 million of contingent consideration, including EBITDA-based payments of up to $25 million in the aggregate and two potential $10 million revenue-based payments, subject to the terms and calculation provisions of the Purchase Agreement. Amounts that are earned but not immediately payable under specified annual limitations may roll forward, and specified unpaid amounts accrue interest that is payable in cash on demand and is not counted toward the $45 million maximum. If we undergo a change of control or sell 50% or more of our assets during the earnout period, we must either pay the unpaid balance of the $45 million maximum or pay all earned amounts and cause the acquirer to assume the earnout obligations, and the term loans must be prepaid upon a change of control, which may make us a less attractive acquisition target or reduce the price an acquirer would pay. These obligations could reduce cash available to operate our business, repay indebtedness or make investments and could affect the economics, timing or structure of future strategic transactions. Changes to the acquired business or dispositions that materially reduce the contractually defined revenue or EBITDA may also require reductions to the earnout thresholds, so reducing the business's scope does not necessarily eliminate the earnout exposure.

  • Corporate Activity and Growth - Risk 8
    Certain portions of the acquired business may not transfer to us at the initial closing and ultimately may not transfer at all.

    Certain businesses in individual jurisdictions may not be capable of transfer at the initial closing because of regulatory approvals, permits, third-party consents, employee consultation requirements, entity formation requirements or other legal or operational impediments. In those circumstances, an affected business may remain legally held and operated by Vantive following the initial closing for our economic benefit and account pending a subsequent local closing, and we generally will bear the economic risks and benefits notwithstanding that we do not hold legal title. If a local closing does not occur within the periods specified in the Purchase Agreement, the parties may be required to pursue alternative arrangements and, in certain circumstances, an affected business ultimately may not transfer to us, in which case the jurisdiction would be excluded from the Vantive Transaction and the principal amount of the term loans reduced by the value allocated to it, net of specified wind-down costs. Any delay in or inability to complete a local transfer could disrupt operations, reduce the geographic scope or revenues of the acquired business or reduce the anticipated benefits of the transaction.

  • Corporate Activity and Growth - Risk 9
    The Vantive Transaction will significantly increase the scale, geographic scope and complexity of our operations, and we may be unable to successfully integrate the acquired business.

    The Vantive Transaction will substantially expand our international operations and add significant manufacturing, commercial, regulatory, supply-chain and employee operations, including through the acquisition of businesses in Italy and Korea and the transfer of additional businesses and assets across multiple jurisdictions. Integration will require significant management attention and resources and will require us to integrate personnel, financial controls, information technology, regulatory processes, commercial relationships, manufacturing operations, supply chains and compliance functions across multiple jurisdictions. We also will need to establish or materially expand commercial, operational, financial, human resources, legal and compliance capabilities for portions of the acquired business that historically relied on Vantive's broader organization. These demands could divert management attention from our existing business and cause the costs or difficulties of integration to exceed our expectations.

  • Corporate Activity and Growth - Risk 10
    The separation of the acquired business from Vantive is complex, and we will continue to depend on Vantive and other third parties following closing.

    The acquired business has not historically operated on a standalone basis. Prior to closing, Vantive is required to complete a reorganization to separate and allocate the assets, liabilities, contracts, employees, permits and other rights and operations comprising the acquired business. The Purchase Agreement provides us with certain protections, including approval rights over aspects of the Italian reorganization and limitations on certain changes to the agreed transaction perimeter. Nevertheless, certain assets, permits and contractual rights may require deferred transfer or third-party consent, certain customer contracts cover both acquired and retained products, and certain supply arrangements, manufacturing know-how and support functions upon which the business relies are provided by Vantive, Baxter or other third parties, and certain of those arrangements, including the supply of a priming solution sold under a number of customer contracts, are scheduled to expire in early 2027 without an identified replacement source for all affected markets. Following closing, we also will rely on Vantive for transition services for initial terms of up to 18 months and for the manufacture and supply of certain products for fixed terms, after which we must have established replacement capabilities or qualified alternative sources. Definitive transition services and manufacturing and supply agreements and their service schedules and annexes remain to be completed in accordance with the agreed term sheets before closing; the services and supply arrangements have limited scope and will not replace every function historically provided by Vantive. If these separation activities are delayed or incomplete, Vantive or other suppliers fail to perform, or we are unable to establish replacement capabilities or alternative sources within applicable transition periods, we may experience additional costs or disruptions in manufacturing, product availability, customer service, regulatory activities, financial reporting or other operations.

Read and Evaluate the RiskReserved for Ultimate MembersUpgrade

Risk Highlights Q3, 2026

Main Risk Category
Finance & Corporate
With 25 Risks
Number of Disclosed Risks
53
+18
From last report
S&P 500 Average: 32
Recent Changes
18Risks added
0Risks removed
0Risks changed
Since Sep 2026
Number of Risk Changed
0
No changes from last report
S&P 500 Average: 1

Risk Word Cloud

our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.our ability to retain executiveswe have been, and may continue to be, materially and adversely affected by increases in raw material, labor and transportation costs and may be unable to recover certain costs due to provisions in our contracts that limit price increases, and we may lose other customers due to price sensitivity.customers due to price sensitivitywe have limited capital resources and will likely need additional funding to expand our business. if we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations.unable to sustain our operationswe use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.claims relating to improper handlingour business depends on government funding of health care, and changes could impact our ability to be paid in full for our products, increase prices or cause consolidation in the dialysis provider market.government funding of health caremarket dynamics in the concentrates business have resulted in fluctuating volumes that could lead to the implementation of cost-saving measures that would have a material and adverse effect on our business.implementation of cost-saving measuresif our customers move back to entering into long-term bundled product contracts with suppliers, our business could suffer.long-term bundled product contractswe have limited capital resources and will likely need additional funding to expand our business. if we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations.unable to raise additional capitalthe market price of our common stock has fluctuated in the past, and is likely to continue to be volatile, which could subject us to litigation.price of our common stockour certificate of incorporation, bylaws and delaware law could prevent a third party from acquiring us (even if an acquisition would benefit our stockholders), may limit the ability of our stockholders to replace our management and limit the price that investors might be willing to pay for shares of our common stock.shares of our common stock

Risk Factors Full Breakdown - Total Risks 53

Share Price & Shareholder Rights9 | 17.0%
  • Share Price & Shareholder Rights - Risk 1Added
    The issuance of shares upon conversion of the convertible note could result in substantial dilution to our stockholders, and the convertible note will remain outstanding if required stockholder approval is not obtained.

    As part of the consideration for the Vantive Transaction, we will issue to an affiliate of Vantive a $25 million convertible note that will be convertible at the holder's option at any time into shares of our common stock at an initial conversion price of $14.94 per share, subject to adjustment, and that will bear interest at 3.0% per annum payable in kind by addition to principal. The conversion price increases on the same basis as ordinary PIK interest, so that such interest does not itself increase the shares issuable in respect of the original principal. Until our stockholders approve the issuance under Nasdaq rules, issuances upon conversion, together with other issuances required to be aggregated, may not exceed 19.99% of either the shares of common stock or voting power outstanding immediately before execution of the Purchase Agreement, to the extent the cap is required by Nasdaq rules. The note requires us to seek approval at stockholder meetings subject to specified timing and eligibility provisions, to resubmit the proposal at subsequent annual meetings if approval is not obtained and, in specified circumstances, to hold a special meeting at the holder's request. Stockholder approval is not a condition to completion of the Vantive Transaction. If approval is not obtained and the exchange cap prevents conversion, the applicable principal and accrued and unpaid interest will remain outstanding and continue to accrue interest in accordance with the convertible note. Conversion of the note would materially dilute existing stockholders and could result in an affiliate of Vantive becoming a significant stockholder. We have also agreed to use commercially reasonable efforts to register the shares issuable upon conversion for resale within the timeframe specified in the note, and the existence of the convertible note and the potential issuance or resale of those shares could adversely affect the market price of our common stock.

  • Share Price & Shareholder Rights - Risk 2
    Our business could be impacted as a result of actions by activist stockholders, including as a result of a potential proxy contest for the election of directors at our annual meeting.

    We were subjected to a proxy contest at our 2017 Annual Meeting of Stockholders, which resulted in the negotiation of changes to the Board and the incurrence of substantial costs. A future proxy contest would require us to incur significant legal fees and proxy solicitation expenses and require significant time and attention by management and the Board. The potential of a proxy contest could interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future direction, adversely affect our relationships with customers, suppliers, investors, prospective and current team members and others, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel, any of which could materially and adversely affect our business and operating results. We may also be subject, from time to time, to other legal and business challenges in the operation of our company due to actions instituted by activist stockholders. Responding to such actions, which may include publicity campaigns and, potentially, litigation, could be costly and time-consuming, divert the time and attention of our Board and management from our business, interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future direction, adversely impact our lobbying efforts, adversely affect our relationships with customers, suppliers, prospective and current team members and others, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel, any of which could materially and adversely affect our business and operating results. We cannot predict, and no assurances can be given as to, the outcome or timing of any matters relating to actions by activist stockholders or the ultimate impact on our business, results of operations, financial position and cash flows.

  • Share Price & Shareholder Rights - Risk 3
    The market price of our common stock has fluctuated in the past, and is likely to continue to be volatile, which could subject us to litigation.

    The market price of our common stock has fluctuated and is likely to be subject to further wide fluctuations in response to numerous factors, many of which are beyond our control, such as those in this "Risk Factors" section and others including: - the reporting of sales, operating results and cash resources;- announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;- the entry into, or termination of, key agreements, including key commercial partner agreements;- the loss of key customers;- changes in the structure of healthcare payment systems;- the loss of key employees;- changes in estimates or recommendations by securities analysts, if any, who cover our common stock;- issues in manufacturing our products;- the initiation of, material developments in, or conclusion of litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others; and - the introduction of technological innovations or new therapies that compete with our products. In addition, third parties may engage in trading strategies that result in intentional volatility to and control over our stock price. Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company's securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.

  • Share Price & Shareholder Rights - Risk 4
    We may fail to qualify for continued listing on Nasdaq, which could make it more difficult for our stockholders to sell their shares.

    We are required to satisfy the continued listing requirements of Nasdaq to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share. In 2021, we received a notice from Nasdaq that we were not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market and were unable to regain compliance in the time allotted by Nasdaq. As a result, we moved our listing to The Nasdaq Capital Market and effected an 11-for-1 reverse stock split in May 2022 to regain compliance. While this reverse stock split addressed the listing deficiency, there can be no assurance that we will be able to maintain compliance with the minimum bid price requirement going forward. Our stock price has been volatile and has trended below the minimum closing bid price from time to time. If our common stock were delisted by Nasdaq, we could face significant material adverse consequences, including: - a limited availability of market quotations for our common stock;- reduced liquidity with respect to our common stock;- a determination that our shares are "penny stock," which will require brokers trading in our shares to adhere to more stringent shares, and which may limit demand for our common stock among certain investors;- a limited amount of news and analyst coverage for our company; and - a decreased ability to issue additional securities or obtain additional financing in the future.

  • Share Price & Shareholder Rights - Risk 5
    Shares eligible for future sale may affect the market price of our common stock.

    Any future sales by us of substantial amounts of our common stock, or the possibility of such sales, could adversely affect the market price of our common stock and also impair our ability to raise capital through an offering of our equity securities in the future. In the future, we may issue additional shares or warrants in connection with investments or for other purposes considered advisable by our Board. Any substantial sale of our common stock may have an adverse effect on the market price of our common stock and may dilute the economic value and voting rights of existing stockholders. In addition, as of December 31, 2025, there were 1,170,397 shares issuable upon the exercise of then-outstanding and exercisable stock options, 2,106,167 shares issuable upon the exercise of then-outstanding stock options that were not yet exercisable, and 3,984,484 shares issuable upon the exercise of then-outstanding and exercisable warrants. The market price of the common stock may be depressed by the potential exercise of these options and warrants and the sale of the underlying common stock. The holders of these options and warrants are likely to exercise them when we would otherwise be able to obtain additional capital on more favorable terms than those provided by the options and warrants.

  • Share Price & Shareholder Rights - Risk 6
    If securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our common stock could decline.

    The trading market for our common stock may be impacted by the availability or lack of research and reports that third-party industry or financial analysts publish about us. There are many large, publicly traded companies active in the medical device and biopharmaceutical industry, which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do cover us downgrade our stock, our stock price would likely decline. If we do not receive adequate coverage by reputable analysts that have an understanding of our business and industry, we could fail to achieve visibility in the market, which in turn could cause our stock price to decline.

  • Share Price & Shareholder Rights - Risk 7
    Our certificate of incorporation, bylaws and Delaware law could prevent a third party from acquiring us (even if an acquisition would benefit our stockholders), may limit the ability of our stockholders to replace our management and limit the price that investors might be willing to pay for shares of our common stock.

    Our certificate of incorporation and bylaws could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, control of us. These provisions could delay or prevent a change in control of the company and could limit the price that investors might be willing to pay in the future for shares of our common stock. These provisions, among other things: - establish a staggered Board divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;- authorize our Board to issue new series of preferred stock without stockholder approval and create, subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;- disallow our stockholders to fill vacancies on our board;- establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;- permit our Board to establish the number of directors between three and fifteen;- provide that stockholders can remove directors only for cause and only upon the approval of not less than a majority of all outstanding shares of our voting stock;- require the approval of not less than a majority of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and - limit the jurisdictions in which certain stockholder litigation may be brought.

  • Share Price & Shareholder Rights - Risk 8
    We are not subject to the provisions of Section 203 of the Delaware General Corporation Law, which could negatively affect your investment.

    We elected in our certificate of incorporation to not be subject to the provisions of Section 203 of the Delaware General Corporation Law ("Section 203"). In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A "business combination" includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An "interested stockholder" is a person who, together with affiliates and associates, owns (or, in certain cases, within three years prior, did own) 15% or more of the corporation's voting stock. This may make us more vulnerable to takeovers that are completed without the approval of our Board and/or without giving us the ability to prohibit or delay such takeovers as effectively.

  • Share Price & Shareholder Rights - Risk 9
    Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

    Our certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court or a federal court located within the State of Delaware) is the exclusive forum for any claims that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity, or as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery. This provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any have exclusive jurisdiction. This choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees. If a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.

See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

FAQ

What are “Risk Factors”?
Risk factors are any situations or occurrences that could make investing in a company risky. The Securities and Exchange Commission (SEC) requires that publicly traded companies disclose their most significant risk factors. This is so that potential investors can consider any risks before they make an investment. They also offer companies protection, as a company can use risk factors as liability protection. This could happen if a company underperforms and investors take legal action as a result. It is worth noting that smaller companies, that is those with a public float of under $75 million on the last business day, do not have to include risk factors in their 10-K and 10-Q forms, although some may choose to do so.
How do companies disclose their risk factors?
Publicly traded companies initially disclose their risk factors to the SEC through their S-1 filings as part of the IPO process. Additionally, companies must provide a complete list of risk factors in their Annual Reports (Form 10-K) or (Form 20-F) for “foreign private issuers”. Quarterly Reports also include a section on risk factors (Form 10-Q) where companies are only required to update any changes since the previous report. According to the SEC, risk factors should be reported concisely, logically and in “plain English” so investors can understand them.
How can I use TipRanks risk factors in my stock research?
Use the Risk Factors tab to get data about the risk factors of any company in which you are considering investing. You can easily see the most significant risks a company is facing. Additionally, you can find out which risk factors a company has added, removed or adjusted since its previous disclosure. You can also see how a company’s risk factors compare to others in its sector. Without reading company reports or participating in conference calls, you would most likely not have access to this sort of information, which is usually not included in press releases or other public announcements. A simplified analysis of risk factors is unique to TipRanks.
What are all the risk factor categories?
TipRanks has identified 6 major categories of risk factors and a number of subcategories for each. You can see how these categories are broken down in the list below. 1. Financial & Corporate Accounting & Financial Operations - risks related to accounting loss, value of intangible assets, financial statements, value of intangible assets, financial reporting, estimates, guidance, company profitability, dividends, fluctuating results. Share Price & Shareholder Rights – risks related to things that impact share prices and the rights of shareholders, including analyst ratings, major shareholder activity, trade volatility, liquidity of shares, anti-takeover provisions, international listing, dual listing. Debt & Financing – risks related to debt, funding, financing and interest rates, financial investments. Corporate Activity and Growth – risks related to restructuring, M&As, joint ventures, execution of corporate strategy, strategic alliances. 2. Legal & Regulatory Litigation and Legal Liabilities – risks related to litigation/ lawsuits against the company. Regulation – risks related to compliance, GDPR, and new legislation. Environmental / Social – risks related to environmental regulation and to data privacy. Taxation & Government Incentives – risks related to taxation and changes in government incentives. 3. Production Costs – risks related to costs of production including commodity prices, future contracts, inventory. Supply Chain – risks related to the company’s suppliers. Manufacturing – risks related to the company’s manufacturing process including product quality and product recalls. Human Capital – risks related to recruitment, training and retention of key employees, employee relationships & unions labor disputes, pension, and post retirement benefits, medical, health and welfare benefits, employee misconduct, employee litigation. 4. Technology & Innovation Innovation / R&D – risks related to innovation and new product development. Technology – risks related to the company’s reliance on technology. Cyber Security – risks related to securing the company’s digital assets and from cyber attacks. Trade Secrets & Patents – risks related to the company’s ability to protect its intellectual property and to infringement claims against the company as well as piracy and unlicensed copying. 5. Ability to Sell Demand – risks related to the demand of the company’s goods and services including seasonality, reliance on key customers. Competition – risks related to the company’s competition including substitutes. Sales & Marketing – risks related to sales, marketing, and distribution channels, pricing, and market penetration. Brand & Reputation – risks related to the company’s brand and reputation. 6. Macro & Political Economy & Political Environment – risks related to changes in economic and political conditions. Natural and Human Disruptions – risks related to catastrophes, floods, storms, terror, earthquakes, coronavirus pandemic/COVID-19. International Operations – risks related to the global nature of the company. Capital Markets – risks related to exchange rates and trade, cryptocurrency.